{"gene":"PAX2","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":1990,"finding":"PAX2 encodes a paired-domain protein expressed in nuclei of developing kidney and nervous system; the protein contains a conserved paired domain and an octapeptide sequence, and at least two protein isoforms are produced from differentially spliced mRNAs.","method":"cDNA cloning, sequencing, in situ hybridization, immunocytochemistry","journal":"Development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct cloning and immunolocalization in two independent papers, single lab, consistent results","pmids":["1977574","1977575"],"is_preprint":false},{"year":1992,"finding":"PAX2 protein can bind a DNA sequence recognized by the Drosophila paired domain, confirming its function as a sequence-specific DNA-binding transcription factor; nuclear localization was demonstrated in condensing mesenchyme cells and their epithelial derivatives in the developing kidney.","method":"DNA-binding assay (EMSA using paired-domain recognition sequence), immunocytochemistry on developing kidney sections","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro DNA-binding assay plus direct immunolocalization, replicated across multiple tissue contexts","pmids":["1311084"],"is_preprint":false},{"year":1993,"finding":"PAX2 protein function is required for the earliest phase of mesenchyme-to-epithelium conversion in the developing kidney; reduction of PAX2 protein with antisense oligonucleotides in mouse kidney organ cultures prevents mesenchyme aggregation and sequential morphological changes of epithelial cell formation.","method":"Antisense oligonucleotide-mediated loss-of-function in mouse kidney organ culture, immunostaining with uvomurulin and laminin antibodies","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct loss-of-function with defined cellular phenotype, replicated across multiple experiments; complemented by transgenic gain-of-function data in same era","pmids":["8187639"],"is_preprint":false},{"year":1993,"finding":"Deregulated (persistent) expression of PAX2 in transgenic mice results in histologically abnormal and dysfunctional renal epithelium resembling congenital nephrotic syndrome, demonstrating that repression of PAX2 is required for normal terminal differentiation of renal epithelium.","method":"Transgenic mouse overexpression (four independently derived transgenic embryos and one line), histological and functional analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain-of-function confirmed in multiple independent transgenic lines with defined renal phenotype","pmids":["8383297"],"is_preprint":false},{"year":1995,"finding":"PAX2 is required for multiple steps of urogenital development: homozygous Pax2-null mice lack kidneys, ureters, and genital tracts due to dysgenesis of both ductal and mesenchymal components; Wolffian/Müllerian ducts degenerate, metanephric mesenchyme fails to undergo epithelial transformation, and expression of tissue-specific markers is de-regulated.","method":"Targeted gene knockout in mice (homozygous null), histological and molecular marker analysis","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — definitive loss-of-function knockout with multiple phenotypic readouts, widely replicated","pmids":["8575306"],"is_preprint":false},{"year":1996,"finding":"The C-terminal serine/threonine/proline-rich region of PAX2 contains a potent transactivation domain (~55 amino acids) that is negatively regulated by adjacent extreme C-terminal sequences; both activating and inhibitory domains function as an independent regulatory module, conserved across PAX2, PAX5, PAX8, zebrafish Pax-b and sea urchin Pax-258.","method":"In vitro mutagenesis, transient transfection reporter assays, GAL4 DNA-binding domain fusion experiments in multiple cell types","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution via mutagenesis + reporter assays + GAL4 fusion, tested across multiple cell types and conserved in multiple species orthologs","pmids":["8617244"],"is_preprint":false},{"year":1996,"finding":"PAX2 is required for formation of the optic chiasm and closure of the optic fissure; PAX2-null mice show total ipsilateral optic tracts (agenesis of optic chiasma), coloboma due to optic fissure closure failure, and agenesis of the cochlea and spiral ganglion.","method":"Targeted Pax2 null mutation in mice, neuroanatomical tracing and histological analysis","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — definitive loss-of-function knockout with multiple independent phenotypic readouts across eye and ear","pmids":["8951055"],"is_preprint":false},{"year":1997,"finding":"PAX2 and PAX5 cooperate at the midbrain-hindbrain boundary organizer: compound heterozygous Pax5(+/-)Pax2(+/-) mice show severe loss of inferior colliculi and cerebellar vermis, and Pax5(-/-)Pax2(+/-) mice show complete deletion of posterior midbrain and cerebellum, demonstrating genetic cooperation between the two factors for normal organizer function.","method":"Double-mutant mouse genetics (Pax5 targeted knockout × Krd deletion of Pax2 locus), morphological analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via double-mutant mice with graded allele dosage, clearly defined phenotypic spectrum","pmids":["9159136"],"is_preprint":false},{"year":1998,"finding":"PAX2 expression in human fetal kidney epithelial (HEK293) cells increases WT1 mRNA (~2-fold) and E-cadherin mRNA (~7-fold), and strongly suppresses vimentin mRNA (to ~8% of control), without affecting proliferation rate, suggesting PAX2 directly regulates mesenchyme-to-epithelium gene expression changes during nephrogenesis.","method":"Stable transfection with tetracycline-regulatable PAX2 expression vector, RT-PCR, Western blot","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay in cell culture with multiple gene readouts, single lab","pmids":["9459485"],"is_preprint":false},{"year":2000,"finding":"Tlx, an orphan nuclear receptor, directly regulates Pax2 transcription; a Tlx binding site is present in the Pax2 promoter and is conserved between mouse and human, placing Tlx upstream of PAX2 in retinal development.","method":"Candidate target gene screen, promoter analysis, conservation of Tlx-binding site identified by sequence analysis; Tlx knockout mice showing loss of Pax2 in the retina","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding site identified and corroborated by Tlx knockout phenotype, single lab","pmids":["10706625"],"is_preprint":false},{"year":2000,"finding":"Reduced Pax2 gene dosage (heterozygous) increases apoptosis in normal developing kidneys and inhibits cystic epithelium expansion in cpk polycystic kidney disease mice, without reducing proliferation, demonstrating that PAX2 normally suppresses apoptosis in renal epithelium.","method":"Genetic intercross (cpk × Pax2 heterozygous), histological quantification of cyst growth, apoptosis assays (TUNEL), proliferation assays","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — defined genetic dosage manipulation with multiple orthogonal readouts (cyst size, apoptosis, proliferation)","pmids":["10694420"],"is_preprint":false},{"year":2001,"finding":"PAX2 transactivation domain is specifically phosphorylated by c-Jun N-terminal kinase (JNK), but not ERK1/2 or p38 MAP kinases; JNK phosphorylation of PAX2 is coincident with enhanced PAX2-dependent transcription activation. PAX2 forms a complex with the JNK scaffolding protein JIP1, and this interaction is enhanced by the upstream kinase DLK.","method":"In vitro kinase assays with immunoprecipitated JNK and recombinant GST-Pax2 fusion proteins, transfection reporter assays, co-immunoprecipitation with JIP1","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with recombinant proteins, co-IP of complex, reporter assays all in one study","pmids":["11700324"],"is_preprint":false},{"year":2001,"finding":"PAX2 expression in mouse mammary gland is required for progesterone-stimulated secondary ductal branching and lobular development; PAX2 loss-of-function (transplant of PAX2-null parenchyma) prevents progesterone response. A PAX2–WT1 regulatory axis was identified, with PAX2 required for WT1 mRNA expression in the mammary gland.","method":"Mammary fat pad transplantation of PAX2-null tissue into wild-type hosts, RT-PCR for WT1, double-antibody immunohistochemistry for PAX2/WT1 co-localization","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined loss-of-function with specific progesterone-response phenotype and WT1 molecular readout, single lab","pmids":["11850818"],"is_preprint":false},{"year":2002,"finding":"PAX2 and PAX8 together are essential for specification of the nephric lineage; mouse embryos lacking both Pax2 and Pax8 fail to form any nephric structures (pronephros or later kidneys), do not initiate Lim1 or c-Ret expression, and lose intermediate mesoderm by apoptosis. Retroviral misexpression of Pax2 alone is sufficient to induce ectopic nephric structures in chick intermediate mesoderm and genital ridge.","method":"Double-knockout mouse genetics, retroviral Pax2 misexpression in chick embryos, molecular marker analysis (Lim1, c-Ret), apoptosis assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — double-knockout plus gain-of-function rescue in a second species, multiple molecular readouts","pmids":["12435636"],"is_preprint":false},{"year":2003,"finding":"Groucho/TLE family protein Grg4 interacts with PAX2 and suppresses PAX2 transactivation by specifically inhibiting JNK-mediated phosphorylation of the PAX2 activation domain; this inhibition depends on PAX2 binding to its target DNA and is independent of histone deacetylation.","method":"Co-immunoprecipitation, in vitro phosphorylation assays, reporter transactivation assays, DNA-binding dependency experiments","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro phosphorylation reconstitution plus co-IP of Grg4-PAX2 complex, with mechanistic dissection of DNA-binding and HDAC independence","pmids":["14532124"],"is_preprint":false},{"year":2004,"finding":"Angiotensin II upregulates Pax2 protein and mRNA via the AT2 receptor (not AT1) in embryonic kidney mesenchymal-epithelial cells (MK4), and this signaling is mediated at least in part through the JAK2/STAT pathway; the stimulatory effect is blocked by the AT2 inhibitor PD123319, the JAK2 inhibitor AG490, and the tyrosine kinase inhibitor genistein, but not by AT1, p38, MEK, or JNK inhibitors.","method":"Pharmacological inhibitor dissection in embryonic kidney cell lines and kidney explant culture, Western blot, RT-PCR, immunofluorescence","journal":"Journal of the American Society of Nephrology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple inhibitor experiments with pathway dissection in two model systems, single lab","pmids":["15153556"],"is_preprint":false},{"year":2005,"finding":"PAX2 directly activates WNT4 gene expression during kidney development: PAX2 protein binds three novel PAX2 recognition motifs in the 5'-flanking sequence of human WNT4 (confirmed by EMSA), activates WNT4 promoter activity ~5-fold in co-transfection assays, induces ~7-fold increase in endogenous WNT4 mRNA in proximal tubule cells, and Wnt4 mRNA is reduced ~60% in Pax2 heterozygous fetal kidney mesenchymal condensates.","method":"EMSA, co-transfection reporter assays, RT-PCR in cell line and Pax2 heterozygous fetal kidney","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct DNA binding (EMSA), promoter activation assay, and in vivo genetic dosage validation, multiple orthogonal methods","pmids":["16368682"],"is_preprint":false},{"year":2005,"finding":"PAX2 regulates gene expression at the mid-hindbrain boundary including direct transcriptional activation of Brn1 (Pou3f3) via functional PAX2-binding sites in the Brn1 promoter and upstream regulatory element; PAX2-dependent targets also include En2, Sef, Tapp1, and Ncrms. Dominant-negative Brn1 in chick implicates Brn1 in Fgf8 regulation downstream of Pax2.","method":"cDNA microarray of FACS-sorted GFP+ cells from wild-type vs Pax2-null embryos; identification of PAX2-binding sites by transgenic lacZ reporter analysis; ectopic dominant-negative Brn1 electroporation in chick","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-scale expression profiling plus direct in vivo reporter validation of PAX2 binding sites plus functional rescue experiment in chick","pmids":["15872005"],"is_preprint":false},{"year":2005,"finding":"Pax2 and Pax8 regulate Gata3 expression in the nephric duct: a cDNA microarray screen identified Gata3 as a gene specifically expressed in the pro/mesonephros and regulated by Pax proteins; Gata3 expression in the pronephric anlage coincides with Pax2/Pax8, suggesting direct upstream regulation.","method":"cDNA microarray screen of pro/mesonephros; Gata3 knockout phenotypic analysis (Ires-GFP knockin); molecular analysis of Ret expression in Gata3(-/-) nephric duct","journal":"Development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — microarray identification plus genetic loss-of-function with molecular readout, but direct Pax2 binding to Gata3 promoter not demonstrated in this paper","pmids":["16319112"],"is_preprint":false},{"year":2002,"finding":"Pax2 activates the mid-hindbrain boundary enhancer of Brn1 and maintains its own expression via auto- and cross-regulatory control: functional PAX2/5/8-binding sites in a proximal enhancer maintain Pax2 expression at the mid-hindbrain boundary; an early 120 bp enhancer requires homeodomain binding sites (including a POU homeodomain site bound by Oct3/4) for initial activation.","method":"Transgenic reporter analysis in mice, site-directed mutagenesis of enhancer binding sites, BAC transgene deletion analysis, electrophoretic mobility assays","journal":"Development","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis of cis-regulatory elements combined with in vivo transgenic reporter assays and BAC deletion validation","pmids":["11807024"],"is_preprint":false},{"year":2008,"finding":"PAX2 mediates ER-dependent repression of ERBB2 transcription in response to tamoxifen in breast cancer cells: tamoxifen-ER complexes repress ERBB2 via a cis-regulatory element in the ERBB2 gene, and PAX2 is a critical mediator of this repression. PAX2 and the ER co-activator AIB1/SRC-3 compete for binding and regulation of ERBB2 transcription, with the outcome determining tamoxifen response.","method":"Reporter assays, ChIP, siRNA knockdown of PAX2, competition binding experiments between PAX2 and AIB1/SRC-3 at the ERBB2 locus in human breast cancer cell lines","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, reporter assays, and siRNA phenotypic rescue with defined molecular competitor, multiple orthogonal methods in one rigorous study","pmids":["19005469"],"is_preprint":false},{"year":2008,"finding":"PAX2 directly activates WNT5A gene expression; PAX2 binds to the WNT5A promoter (confirmed by chromatin immunoprecipitation and EMSA), and transactivation assays demonstrate direct PAX2-dependent regulation of WNT5A in HEK293 cells.","method":"Chromatin immunoprecipitation, EMSA, transactivation assays in HEK293 cells","journal":"Neoplasia","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct DNA binding confirmed by both ChIP and EMSA plus functional transactivation assay","pmids":["19048125"],"is_preprint":false},{"year":2008,"finding":"Pax2 coordinates optic cup morphogenesis and cell fate independently: in the absence of Pax2, otic progenitors fail to elongate due to loss of apically localized N-cadherin and N-CAM; misexpression of Pax2 leads to ectopic activation of both adhesion molecules but is not sufficient to confer otic identity, indicating Pax2 controls cell shape independently from cell identity.","method":"Pax2 loss-of-function and gain-of-function in chick inner ear, immunofluorescence for N-cadherin, N-CAM, otic marker expression","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complementary loss- and gain-of-function in same tissue with defined molecular adhesion molecule readout, single lab","pmids":["20643116"],"is_preprint":false},{"year":2009,"finding":"BMP7 and SHH activate Pax2 expression in mouse retinal astrocyte precursors; SHH may regulate BMP7 expression, and BMP and SHH pathway members interact with TLX (a tailless transcription factor family repressor) to relieve TLX-mediated repression of Pax2 expression.","method":"In vitro and ex vivo retinal astrocyte precursor cultures with BMP7 and SHH treatment; pathway inhibitor experiments; demonstrated TLX interaction with BMP and SHH pathway members by co-immunoprecipitation","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional pathway dissection in primary cells with inhibitor experiments and co-IP of TLX interactions, single lab","pmids":["19505455"],"is_preprint":false},{"year":2011,"finding":"PAX2 directly binds the ADAM10 promoter and regulates ADAM10 protein expression in renal cancer cells; PAX2 knockdown reduces ADAM10 (a major sheddase for L1-CAM and c-Met), leading to increased L1-CAM expression and activation of PI3K/Akt signaling via soluble L1-CAM.","method":"ChIP, PAX2 siRNA knockdown, PAX2 overexpression, L1-CAM and ADAM10 protein measurements in renal cancer cell lines","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms direct promoter binding, with downstream pathway validation by knockdown, single lab","pmids":["21880579"],"is_preprint":false},{"year":2011,"finding":"PAX2 directly regulates ADAM10 expression in melanoma cells (confirmed by ChIP and PAX2 overexpression/siRNA); PAX2 knockdown inhibits anchorage-independent cell growth, migration, and invasion and restores cisplatin sensitivity in melanoma cells.","method":"ChIP, PAX2 siRNA knockdown, PAX2 overexpression, soft agar assays, migration/invasion assays, drug sensitivity assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms direct binding, multiple functional readouts by siRNA and overexpression, single lab","pmids":["21876729"],"is_preprint":false},{"year":2014,"finding":"FSGS-associated PAX2 missense mutations perturb protein function by affecting DNA binding and transactivation activity, or by altering interaction with repressor proteins resulting in enhanced repressor activity; these effects were documented by in vitro functional studies guided by in silico structural modeling.","method":"In vitro functional studies (DNA-binding and transactivation assays), in silico structural modeling of PAX2 missense variants","journal":"Journal of the American Society of Nephrology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro functional assays with multiple mutants, structural modeling, but single lab","pmids":["24676634"],"is_preprint":false},{"year":2015,"finding":"PAX2 specifies the intermediate mesoderm and renal progenitor cells through epigenetic mechanisms dependent on the adaptor protein PTIP: PAX2 recruits PTIP-dependent histone methyltransferase complexes to activate early Pax2 target genes; loss of PTIP in kidney organ culture prevents full activation of later-expressed Pax2 target genes, while early Pax2 targets remain on once activated. PAX2 also represses paraxial mesodermal fate.","method":"EGFP knock-in allele cell sorting, gene expression profiling of Pax2 mutant vs wild-type intermediate mesoderm cells, conditional PTIP deletion in kidney organ culture, chromatin analysis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (FACS-sorted transcriptomics, conditional PTIP KO, epigenetic mechanism) in a single rigorous study","pmids":["25617721"],"is_preprint":false},{"year":2015,"finding":"PAX2 directly binds the IL-5 promoter and activates IL-5 expression in esophageal cancer cells, promoting tumor metastasis; two PAX2 binding sites were identified in the IL-5 promoter, and PAX2 stimulated IL-5 promoter activity, with ChIP confirming direct binding.","method":"ChIP, promoter reporter assays, PAX2 overexpression and shRNA knockdown in ESCC cell lines, microarray analysis","journal":"Cellular physiology and biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assays confirm direct binding, functional invasion/metastasis assays, single lab","pmids":["25613757"],"is_preprint":false},{"year":2020,"finding":"PAX2 and PAX8 are required in adult renal collecting duct epithelia for urine concentration: induced deletion of both Pax2 and Pax8 in adult mice causes severe polyuria attributable to loss of urea transporters (Slc14a2) and aquaporins in inner/outer medulla. Pax8 is induced by high-salt in collecting duct cells and activates Slc14a2 by recruiting a histone methyltransferase complex to its promoter.","method":"Inducible conditional knockout of Pax2 and/or Pax8 in adult mice, gene expression analysis, ChIP for histone methyltransferase complex recruitment to Slc14a2 promoter in inner medullary collecting duct cells","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible adult-specific conditional KO with defined physiological phenotype plus mechanistic ChIP for epigenetic target gene activation","pmids":["32381599"],"is_preprint":false},{"year":2022,"finding":"PAX2 binds in the vicinity of estrogen-promoted progesterone receptor (PR) binding sites in endometrial cancer cells and fine-tunes ERalpha and PR interplay in transcriptional regulation; PAX2 knockdown alters expression of hormone-regulated genes at these 'progestin control regions' (PgCRs) which have open chromatin even before hormone exposure.","method":"ChIP-seq for PAX2, ER, PR in hormone-treated Ishikawa endometrial cancer cells; Hi-C; ATAC-seq; PAX2 siRNA knockdown with RNA-seq","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq, chromatin conformation (Hi-C), ATAC-seq, and functional knockdown in one rigorous study","pmids":["35018885"],"is_preprint":false}],"current_model":"PAX2 is a sequence-specific DNA-binding transcription factor (via its paired domain) that activates or represses target genes (including WNT4, WNT5A, ERBB2, ADAM10, IL-5, Brn1/Pou3f3, Slc14a2) in a context-dependent manner; its transactivation activity is enhanced by JNK-mediated phosphorylation of its C-terminal serine/threonine-rich domain and suppressed by Groucho/TLE (Grg4)-mediated inhibition of that phosphorylation; it recruits PTIP-dependent histone methyltransferase complexes to epigenetically activate renal progenitor target genes; it is required for mesenchyme-to-epithelium transition and nephric lineage specification (cooperating with PAX8), and its expression must be extinguished for terminal differentiation of renal tubular epithelium, while persistent expression promotes cystic, dysplastic, or neoplastic renal growth."},"narrative":{"mechanistic_narrative":"PAX2 is a paired-domain, sequence-specific DNA-binding transcription factor that governs urogenital and neural development by activating or repressing lineage-specific target genes [PMID:1977574, PMID:1977575, PMID:1311084]. It is required for the earliest mesenchyme-to-epithelium conversion of the metanephric mesenchyme, and embryos lacking PAX2 (or both PAX2 and its partner PAX8) fail to form kidneys, ureters, and genital tracts, while PAX2/PAX8 double loss abolishes nephric lineage specification altogether and PAX2 misexpression alone induces ectopic nephric structures [PMID:8187639, PMID:8575306, PMID:12435636]. PAX2 also patterns the optic chiasm, optic fissure, cochlea, and—cooperating with PAX5—the midbrain-hindbrain boundary organizer [PMID:8951055, PMID:9159136]. Its transcriptional outputs include direct activation of WNT4, WNT5A, the midbrain-hindbrain factor Brn1/Pou3f3, and a self-maintaining enhancer of its own locus, and it drives epithelial gene programs (raising WT1 and E-cadherin while suppressing vimentin) [PMID:16368682, PMID:19048125, PMID:15872005, PMID:11807024, PMID:9459485]. PAX2 transactivation is positively regulated by JNK-mediated phosphorylation of its C-terminal serine/threonine-rich activation module—an interaction scaffolded by JIP1 and DLK—and is antagonized by Groucho/TLE protein Grg4, which suppresses this phosphorylation in a DNA-binding-dependent, HDAC-independent manner [PMID:8617244, PMID:11700324, PMID:14532124]. PAX2 specifies intermediate mesoderm and renal progenitors epigenetically by recruiting PTIP-dependent histone methyltransferase complexes to activate target genes, and PAX2/PAX8 sustain adult collecting-duct urine-concentrating genes such as Slc14a2 through the same epigenetic machinery [PMID:25617721, PMID:32381599]. Because PAX2 suppresses renal epithelial apoptosis and its persistence blocks terminal differentiation, deregulated PAX2 produces dysplastic, cystic renal phenotypes, and PAX2 is co-opted in cancers where it regulates ERBB2, ADAM10, and IL-5 [PMID:8383297, PMID:10694420, PMID:19005469, PMID:21880579, PMID:25613757]. FSGS-associated PAX2 missense mutations disrupt DNA binding and transactivation or enhance repressor interactions, linking PAX2 dysfunction to human renal disease [PMID:24676634].","teleology":[{"year":1990,"claim":"Establishing that PAX2 encodes a nuclear paired-domain protein expressed in developing kidney and nervous system defined it as a candidate developmental transcription factor and revealed isoform diversity.","evidence":"cDNA cloning, sequencing, in situ hybridization and immunocytochemistry","pmids":["1977574","1977575"],"confidence":"Medium","gaps":["DNA-binding activity not yet demonstrated","functional roles of distinct isoforms unresolved"]},{"year":1992,"claim":"Demonstrating that PAX2 binds a paired-domain recognition sequence confirmed it acts as a sequence-specific DNA-binding transcription factor in the developing kidney.","evidence":"EMSA with paired-domain recognition sequence plus immunolocalization on kidney sections","pmids":["1311084"],"confidence":"High","gaps":["no endogenous target genes identified","activator vs repressor function not yet defined"]},{"year":1993,"claim":"Loss- and gain-of-function showed PAX2 is required for mesenchyme-to-epithelium conversion and that its persistence blocks terminal differentiation, defining a window of required expression.","evidence":"antisense knockdown in mouse kidney organ culture; transgenic overexpression in mice","pmids":["8187639","8383297"],"confidence":"High","gaps":["direct transcriptional targets driving conversion not identified","mechanism of required down-regulation unknown"]},{"year":1995,"claim":"Targeted knockout established that PAX2 is essential across urogenital development, with null mice lacking kidneys, ureters, and genital tracts.","evidence":"homozygous Pax2-null mice with histological and marker analysis","pmids":["8575306"],"confidence":"High","gaps":["cell-autonomous vs non-autonomous requirements not dissected","molecular targets in each duct lineage unknown"]},{"year":1996,"claim":"Mapping the C-terminal transactivation module and extending null phenotypes to eye and ear revealed both the regulatory architecture of PAX2 and the breadth of its developmental roles.","evidence":"GAL4 fusion/mutagenesis reporter assays; Pax2-null neuroanatomical analysis","pmids":["8617244","8951055"],"confidence":"High","gaps":["signals controlling the inhibitory module unknown at this stage","neural target genes not identified"]},{"year":1997,"claim":"Double-mutant genetics demonstrated PAX2-PAX5 cooperation at the midbrain-hindbrain organizer, establishing functional redundancy among PAX family members in dosage-sensitive patterning.","evidence":"Pax5 knockout × Pax2 (Krd) deletion compound-mutant mouse genetics","pmids":["9159136"],"confidence":"High","gaps":["shared vs distinct target genes not resolved","biochemical basis of cooperation unknown"]},{"year":1998,"claim":"Inducible PAX2 expression in human kidney epithelial cells linked PAX2 to the epithelial gene program by raising WT1 and E-cadherin and suppressing vimentin.","evidence":"tetracycline-regulated PAX2 stable transfection with RT-PCR and Western blot in HEK293","pmids":["9459485"],"confidence":"Medium","gaps":["direct vs indirect regulation of these genes not established","single cell-line context"]},{"year":2000,"claim":"Identification of Tlx as a direct upstream regulator and the demonstration that PAX2 suppresses renal epithelial apoptosis placed PAX2 within signaling hierarchies and clarified its growth-permissive role.","evidence":"promoter binding-site analysis with Tlx knockout; cpk × Pax2-heterozygous intercross with TUNEL and proliferation assays","pmids":["10706625","10694420"],"confidence":"High","gaps":["anti-apoptotic target genes of PAX2 not identified","Tlx site occupancy not validated in vivo by ChIP"]},{"year":2001,"claim":"Discovery that JNK phosphorylates the PAX2 transactivation domain—scaffolded by JIP1/DLK—and that PAX2 controls progesterone-driven mammary branching connected signaling to PAX2 transcriptional output across tissues.","evidence":"in vitro JNK kinase assays, co-IP with JIP1, reporter assays; PAX2-null mammary fat-pad transplantation with WT1 readout","pmids":["11700324","11850818"],"confidence":"High","gaps":["phosphoacceptor residues and their in vivo requirement not mapped","MAPK pathway specificity in vivo not tested"]},{"year":2002,"claim":"Defining PAX2/PAX8 redundancy for nephric lineage specification and the auto/cross-regulatory enhancer at the mid-hindbrain boundary revealed how PAX2 establishes and maintains its own expression domains.","evidence":"Pax2/Pax8 double-knockout and chick retroviral misexpression; transgenic reporter mutagenesis and BAC deletion of Pax2 enhancers","pmids":["12435636","11807024"],"confidence":"High","gaps":["direct targets initiating nephric specification not enumerated","biochemical basis of PAX2/PAX8 functional equivalence unresolved"]},{"year":2003,"claim":"Showing that Grg4/TLE suppresses PAX2 transactivation by inhibiting JNK-mediated phosphorylation defined the molecular switch toggling PAX2 between active and repressed states.","evidence":"co-IP, in vitro phosphorylation, reporter assays with DNA-binding-dependency tests","pmids":["14532124"],"confidence":"High","gaps":["in vivo developmental contexts of Grg4 antagonism not mapped","how Grg4 mechanistically blocks the kinase unknown"]},{"year":2004,"claim":"Linking Angiotensin II/AT2 signaling through JAK2/STAT to PAX2 induction extended the upstream regulatory network controlling PAX2 abundance in nephrogenic cells.","evidence":"pharmacological inhibitor dissection in embryonic kidney cells and explants","pmids":["15153556"],"confidence":"Medium","gaps":["direct STAT binding to the Pax2 promoter not shown","single-lab pharmacological evidence"]},{"year":2005,"claim":"Direct identification of WNT4, Brn1/Pou3f3, and other targets (with En2, Sef, Gata3) converted PAX2 from a genetically required factor into a defined transcriptional activator of developmental programs.","evidence":"EMSA/ChIP and reporter assays for WNT4; microarray plus transgenic lacZ reporter validation for Brn1 and mid-hindbrain targets; microarray for Gata3","pmids":["16368682","15872005","16319112"],"confidence":"High","gaps":["genome-wide direct binding map not yet available","Gata3 direct promoter binding not demonstrated"]},{"year":2008,"claim":"Identification of WNT5A as a direct target and the discovery that PAX2 mediates tamoxifen-induced ERBB2 repression revealed PAX2 functions in cancer-relevant transcriptional contexts.","evidence":"ChIP/EMSA/reporter assays for WNT5A; ChIP, siRNA, and AIB1/SRC-3 competition assays at ERBB2 in breast cancer cells","pmids":["19048125","19005469"],"confidence":"High","gaps":["determinants of PAX2 activator-vs-repressor outcome at a given locus unresolved","in vivo relevance of ERBB2 repression beyond cell lines"]},{"year":2011,"claim":"Demonstrating PAX2 direct regulation of ADAM10 in renal cancer and melanoma connected PAX2 to sheddase-driven L1-CAM/PI3K-Akt signaling and tumor cell aggressiveness.","evidence":"ChIP, siRNA, overexpression with invasion/migration and drug-sensitivity assays in renal and melanoma cell lines","pmids":["21880579","21876729"],"confidence":"Medium","gaps":["in vivo tumor relevance not established","single-lab cell-line evidence"]},{"year":2015,"claim":"Establishing the PAX2-PTIP axis showed that PAX2 specifies renal progenitors epigenetically by recruiting histone methyltransferase complexes, and identification of the IL-5 target extended its oncogenic reach.","evidence":"FACS-sorted transcriptomics with conditional PTIP deletion in kidney organ culture; ChIP and reporter assays for IL-5 in ESCC cells","pmids":["25617721","25613757"],"confidence":"High","gaps":["identity of the recruited HMT complex components not fully defined","how early vs late targets are differentially maintained mechanistically unresolved"]},{"year":2020,"claim":"Inducible adult deletion revealed an ongoing PAX2/PAX8 requirement for urine concentration via epigenetic activation of Slc14a2 and aquaporins, showing PAX2 function extends beyond development.","evidence":"inducible conditional Pax2/Pax8 knockout in adult mice with expression analysis and ChIP for HMT recruitment to Slc14a2","pmids":["32381599"],"confidence":"High","gaps":["relative contributions of PAX2 vs PAX8 in adult collecting duct not fully separated","salt-sensing mechanism upstream of induction unresolved"]},{"year":2022,"claim":"Genome-wide mapping in endometrial cancer placed PAX2 at estrogen/progesterone-responsive regulatory regions, defining a role in fine-tuning hormone-receptor transcriptional interplay.","evidence":"PAX2/ER/PR ChIP-seq, Hi-C, ATAC-seq and siRNA RNA-seq in Ishikawa cells","pmids":["35018885"],"confidence":"High","gaps":["mechanism by which PAX2 modulates ER/PR output at PgCRs unresolved","in vivo endometrial relevance not tested"]},{"year":2014,"claim":"Functional characterization of FSGS-associated PAX2 missense variants established that disease mutations act by impairing DNA binding/transactivation or enhancing repressor interactions, linking PAX2 dysfunction to human renal disease.","evidence":"in vitro DNA-binding and transactivation assays guided by in silico structural modeling","pmids":["24676634"],"confidence":"Medium","gaps":["genotype-phenotype correlations not established in vivo","single-lab functional assays"]},{"year":null,"claim":"How PAX2 selects between activation and repression at a given locus, and the full composition of the histone methyltransferase machinery it recruits, remain unresolved.","evidence":"no single timeline study reconciles context-dependent activator/repressor switching with the recruited epigenetic complexes","pmids":[],"confidence":"Medium","gaps":["determinants of activator-vs-repressor outcome unknown","subunit composition of recruited HMT complexes incompletely defined","structural basis of paired-domain target selection in vivo not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,16,21,24]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[5,16,17,20,21]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[14,30]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,4,6,7,13]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[16,17,20,21]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[27,29]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,26]}],"complexes":[],"partners":["PAX8","PAX5","TLE4","JIP1","PTIP","WT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q02962","full_name":"Paired box protein Pax-2","aliases":[],"length_aa":417,"mass_kda":44.7,"function":"Transcription factor that may have a role in kidney cell differentiation (PubMed:24676634). Has a critical role in the development of the urogenital tract, the eyes, and the CNS","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q02962/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PAX2","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PAX2","total_profiled":1310},"omim":[{"mim_id":"620164","title":"ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 26; ZBTB26","url":"https://www.omim.org/entry/620164"},{"mim_id":"616741","title":"PR DOMAIN-CONTAINING PROTEIN 13; PRDM13","url":"https://www.omim.org/entry/616741"},{"mim_id":"616002","title":"FOCAL SEGMENTAL GLOMERULOSCLEROSIS 7; FSGS7","url":"https://www.omim.org/entry/616002"},{"mim_id":"611608","title":"MICRO RNA 183; MIR183","url":"https://www.omim.org/entry/611608"},{"mim_id":"611607","title":"MICRO RNA 182; MIR182","url":"https://www.omim.org/entry/611607"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"epididymis","ntpm":28.0},{"tissue":"kidney","ntpm":94.2}],"url":"https://www.proteinatlas.org/search/PAX2"},"hgnc":{"alias_symbol":["PAX-2"],"prev_symbol":[]},"alphafold":{"accession":"Q02962","domains":[{"cath_id":"1.10.10.10","chopping":"17-74","consensus_level":"high","plddt":95.4114,"start":17,"end":74},{"cath_id":"1.10.10.10","chopping":"92-140","consensus_level":"high","plddt":93.4849,"start":92,"end":140}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q02962","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q02962-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q02962-F1-predicted_aligned_error_v6.png","plddt_mean":60.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PAX2","jax_strain_url":"https://www.jax.org/strain/search?query=PAX2"},"sequence":{"accession":"Q02962","fasta_url":"https://rest.uniprot.org/uniprotkb/Q02962.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q02962/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q02962"}},"corpus_meta":[{"pmid":"8575306","id":"PMC_8575306","title":"Pax-2 controls multiple steps of urogenital development.","date":"1995","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/8575306","citation_count":699,"is_preprint":false},{"pmid":"1977574","id":"PMC_1977574","title":"Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system.","date":"1990","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/1977574","citation_count":502,"is_preprint":false},{"pmid":"8951055","id":"PMC_8951055","title":"Pax2 contributes to inner ear patterning and optic nerve trajectory.","date":"1996","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/8951055","citation_count":492,"is_preprint":false},{"pmid":"12435636","id":"PMC_12435636","title":"Nephric lineage specification by Pax2 and Pax8.","date":"2002","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/12435636","citation_count":412,"is_preprint":false},{"pmid":"1977575","id":"PMC_1977575","title":"Spatially and temporally restricted expression of Pax2 during murine neurogenesis.","date":"1990","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/1977575","citation_count":371,"is_preprint":false},{"pmid":"1311084","id":"PMC_1311084","title":"Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1311084","citation_count":368,"is_preprint":false},{"pmid":"8383297","id":"PMC_8383297","title":"Deregulation of Pax-2 expression in transgenic mice generates severe kidney abnormalities.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8383297","citation_count":260,"is_preprint":false},{"pmid":"8187639","id":"PMC_8187639","title":"Pax-2 is required for mesenchyme-to-epithelium conversion during kidney development.","date":"1993","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/8187639","citation_count":259,"is_preprint":false},{"pmid":"16319112","id":"PMC_16319112","title":"Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16319112","citation_count":253,"is_preprint":false},{"pmid":"19005469","id":"PMC_19005469","title":"Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.","date":"2008","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/19005469","citation_count":248,"is_preprint":false},{"pmid":"15083520","id":"PMC_15083520","title":"Generation of Pax2-Cre mice by modification of a Pax2 bacterial artificial chromosome.","date":"2004","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/15083520","citation_count":247,"is_preprint":false},{"pmid":"17314325","id":"PMC_17314325","title":"Pax2 and pax8 regulate branching morphogenesis and nephron differentiation in the developing kidney.","date":"2007","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/17314325","citation_count":183,"is_preprint":false},{"pmid":"10512984","id":"PMC_10512984","title":"Pax-2 expression defines a subset of GABAergic interneurons and their precursors in the developing murine cerebellum.","date":"1999","source":"Journal of neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/10512984","citation_count":181,"is_preprint":false},{"pmid":"10504494","id":"PMC_10504494","title":"Re-expression of the developmental gene Pax-2 during experimental acute tubular necrosis in mice 1.","date":"1999","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/10504494","citation_count":161,"is_preprint":false},{"pmid":"1457381","id":"PMC_1457381","title":"Comparative analysis of Pax-2 protein distributions during neurulation in mice and zebrafish.","date":"1992","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/1457381","citation_count":154,"is_preprint":false},{"pmid":"9159136","id":"PMC_9159136","title":"Cooperation of Pax2 and Pax5 in midbrain and cerebellum development.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9159136","citation_count":144,"is_preprint":false},{"pmid":"8617244","id":"PMC_8617244","title":"C-terminal activating and inhibitory domains determine the transactivation potential of BSAP (Pax-5), Pax-2 and Pax-8.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8617244","citation_count":133,"is_preprint":false},{"pmid":"20727173","id":"PMC_20727173","title":"Pax2 and Pax8 cooperate in mouse inner ear morphogenesis and innervation.","date":"2010","source":"BMC developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20727173","citation_count":128,"is_preprint":false},{"pmid":"1378753","id":"PMC_1378753","title":"Expression of the PAX2 gene in human fetal kidney and Wilms' tumor.","date":"1992","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/1378753","citation_count":126,"is_preprint":false},{"pmid":"11793341","id":"PMC_11793341","title":"Expression of the transcription factors GATA3 and Pax2 during development of the mammalian inner ear.","date":"2002","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11793341","citation_count":124,"is_preprint":false},{"pmid":"9486533","id":"PMC_9486533","title":"Xenopus Pax-2 displays multiple splice forms during embryogenesis and pronephric kidney development.","date":"1997","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/9486533","citation_count":121,"is_preprint":false},{"pmid":"20597068","id":"PMC_20597068","title":"Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube.","date":"2010","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20597068","citation_count":120,"is_preprint":false},{"pmid":"7664285","id":"PMC_7664285","title":"Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7664285","citation_count":117,"is_preprint":false},{"pmid":"15502805","id":"PMC_15502805","title":"Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study.","date":"2005","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/15502805","citation_count":113,"is_preprint":false},{"pmid":"10706625","id":"PMC_10706625","title":"The orphan nuclear receptor Tlx regulates Pax2 and is essential for vision.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10706625","citation_count":107,"is_preprint":false},{"pmid":"20631067","id":"PMC_20631067","title":"Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20631067","citation_count":105,"is_preprint":false},{"pmid":"20562848","id":"PMC_20562848","title":"High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression.","date":"2010","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/20562848","citation_count":100,"is_preprint":false},{"pmid":"10535325","id":"PMC_10535325","title":"Pax2 in development and renal disease.","date":"1999","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10535325","citation_count":95,"is_preprint":false},{"pmid":"24676634","id":"PMC_24676634","title":"Mutations in PAX2 associate with adult-onset FSGS.","date":"2014","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/24676634","citation_count":95,"is_preprint":false},{"pmid":"10694420","id":"PMC_10694420","title":"Reduced Pax2 gene dosage increases apoptosis and slows the progression of renal cystic disease.","date":"2000","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10694420","citation_count":92,"is_preprint":false},{"pmid":"21989345","id":"PMC_21989345","title":"PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison.","date":"2011","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21989345","citation_count":91,"is_preprint":false},{"pmid":"9916932","id":"PMC_9916932","title":"WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9916932","citation_count":85,"is_preprint":false},{"pmid":"11807024","id":"PMC_11807024","title":"The activation and maintenance of Pax2 expression at the mid-hindbrain boundary is controlled by separate enhancers.","date":"2002","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11807024","citation_count":85,"is_preprint":false},{"pmid":"10354469","id":"PMC_10354469","title":"Pax2/5 and Pax6 subdivide the early neural tube into three domains.","date":"1999","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/10354469","citation_count":83,"is_preprint":false},{"pmid":"18634777","id":"PMC_18634777","title":"Ptf1a, Lbx1 and Pax2 coordinate glycinergic and peptidergic transmitter phenotypes in dorsal spinal inhibitory neurons.","date":"2008","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/18634777","citation_count":82,"is_preprint":false},{"pmid":"23194047","id":"PMC_23194047","title":"PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.","date":"2012","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23194047","citation_count":79,"is_preprint":false},{"pmid":"19525924","id":"PMC_19525924","title":"PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.","date":"2009","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/19525924","citation_count":78,"is_preprint":false},{"pmid":"9473325","id":"PMC_9473325","title":"Pax2 expression and retinal morphogenesis in the normal and Krd mouse.","date":"1998","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/9473325","citation_count":74,"is_preprint":false},{"pmid":"11274636","id":"PMC_11274636","title":"Pax-2 expression in adult renal tumors.","date":"2001","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11274636","citation_count":73,"is_preprint":false},{"pmid":"12444203","id":"PMC_12444203","title":"Involvement of Pax-2 in the action of activin A on tubular cell regeneration.","date":"2002","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/12444203","citation_count":73,"is_preprint":false},{"pmid":"11700324","id":"PMC_11700324","title":"Phosphorylation of Pax2 by the c-Jun N-terminal kinase and enhanced Pax2-dependent transcription activation.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11700324","citation_count":72,"is_preprint":false},{"pmid":"14532124","id":"PMC_14532124","title":"Groucho suppresses Pax2 transactivation by inhibition of JNK-mediated phosphorylation.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/14532124","citation_count":72,"is_preprint":false},{"pmid":"11093271","id":"PMC_11093271","title":"PAX2 mutations in renal-coloboma syndrome: mutational hotspot and germline mosaicism.","date":"2000","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/11093271","citation_count":66,"is_preprint":false},{"pmid":"19951611","id":"PMC_19951611","title":"Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas.","date":"2009","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19951611","citation_count":63,"is_preprint":false},{"pmid":"11850818","id":"PMC_11850818","title":"Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11850818","citation_count":62,"is_preprint":false},{"pmid":"20216401","id":"PMC_20216401","title":"PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study.","date":"2010","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/20216401","citation_count":61,"is_preprint":false},{"pmid":"20966644","id":"PMC_20966644","title":"The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10.","date":"2010","source":"Advances in anatomic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20966644","citation_count":59,"is_preprint":false},{"pmid":"10446345","id":"PMC_10446345","title":"Roles of Pax-2 in initiation of the chick tectal development.","date":"1999","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10446345","citation_count":59,"is_preprint":false},{"pmid":"15872005","id":"PMC_15872005","title":"Identification of Pax2-regulated genes by expression profiling of the mid-hindbrain organizer region.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15872005","citation_count":57,"is_preprint":false},{"pmid":"16368682","id":"PMC_16368682","title":"PAX2 activates WNT4 expression during mammalian kidney development.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16368682","citation_count":56,"is_preprint":false},{"pmid":"20643116","id":"PMC_20643116","title":"Pax2 coordinates epithelial morphogenesis and cell fate in the inner ear.","date":"2010","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20643116","citation_count":55,"is_preprint":false},{"pmid":"11461952","id":"PMC_11461952","title":"PAX2 gene mutation in a family with isolated renal hypoplasia.","date":"2001","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/11461952","citation_count":55,"is_preprint":false},{"pmid":"19401348","id":"PMC_19401348","title":"Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19401348","citation_count":49,"is_preprint":false},{"pmid":"21880579","id":"PMC_21880579","title":"The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma.","date":"2011","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/21880579","citation_count":46,"is_preprint":false},{"pmid":"9874314","id":"PMC_9874314","title":"The role of PAX2 in normal and abnormal development of the urinary tract.","date":"1998","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/9874314","citation_count":44,"is_preprint":false},{"pmid":"9760197","id":"PMC_9760197","title":"Missense mutation and hexanucleotide duplication in the PAX2 gene in two unrelated families with renal-coloboma syndrome (MIM 120330).","date":"1998","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9760197","citation_count":44,"is_preprint":false},{"pmid":"11371938","id":"PMC_11371938","title":"Expression of the developmental and oncogenic PAX2 gene in human prostate cancer.","date":"2001","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/11371938","citation_count":43,"is_preprint":false},{"pmid":"30511741","id":"PMC_30511741","title":"PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia: A systematic review and meta-analysis of diagnostic accuracy.","date":"2019","source":"Acta obstetricia et gynecologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/30511741","citation_count":42,"is_preprint":false},{"pmid":"10900085","id":"PMC_10900085","title":"Expression of Pax2 and patterning of the chick inner ear.","date":"1999","source":"Journal of neurocytology","url":"https://pubmed.ncbi.nlm.nih.gov/10900085","citation_count":42,"is_preprint":false},{"pmid":"10869107","id":"PMC_10869107","title":"Expression of the PAX2 gene in human embryos and exclusion in the CHARGE syndrome.","date":"2000","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10869107","citation_count":42,"is_preprint":false},{"pmid":"17173889","id":"PMC_17173889","title":"Pax2 regulates neuronal-glial cell fate choice in the embryonic optic nerve.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17173889","citation_count":42,"is_preprint":false},{"pmid":"8827071","id":"PMC_8827071","title":"Pax-2, kidney development, and oncogenesis.","date":"1996","source":"Medical and pediatric oncology","url":"https://pubmed.ncbi.nlm.nih.gov/8827071","citation_count":41,"is_preprint":false},{"pmid":"22138676","id":"PMC_22138676","title":"PAX2 in human kidney malformations and disease.","date":"2011","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/22138676","citation_count":41,"is_preprint":false},{"pmid":"15188273","id":"PMC_15188273","title":"Correlation of Pax-2 expression with cell proliferation in the developing chicken inner ear.","date":"2004","source":"Journal of neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/15188273","citation_count":41,"is_preprint":false},{"pmid":"22080059","id":"PMC_22080059","title":"PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer.","date":"2011","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/22080059","citation_count":41,"is_preprint":false},{"pmid":"16436683","id":"PMC_16436683","title":"Expression of Pax2 in human renal tumor-derived endothelial cells sustains apoptosis resistance and angiogenesis.","date":"2006","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16436683","citation_count":41,"is_preprint":false},{"pmid":"26571382","id":"PMC_26571382","title":"Association of PAX2 and Other Gene Mutations with the Clinical Manifestations of Renal Coloboma Syndrome.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26571382","citation_count":40,"is_preprint":false},{"pmid":"17021039","id":"PMC_17021039","title":"Pax2/5/8 proteins promote cell survival in C. elegans.","date":"2006","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17021039","citation_count":40,"is_preprint":false},{"pmid":"15153556","id":"PMC_15153556","title":"Angiotensin II increases Pax-2 expression in fetal kidney cells via the AT2 receptor.","date":"2004","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/15153556","citation_count":40,"is_preprint":false},{"pmid":"22511595","id":"PMC_22511595","title":"Hnf1b and Pax2 cooperate to control different pathways in kidney and ureter morphogenesis.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22511595","citation_count":38,"is_preprint":false},{"pmid":"31522607","id":"PMC_31522607","title":"miR-744-5p Inhibits Non-Small Cell Lung Cancer Proliferation and Invasion by Directly Targeting PAX2.","date":"2019","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/31522607","citation_count":38,"is_preprint":false},{"pmid":"31060108","id":"PMC_31060108","title":"Diverse phenotypes in children with PAX2-related disorder.","date":"2019","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31060108","citation_count":37,"is_preprint":false},{"pmid":"8482415","id":"PMC_8482415","title":"Aberrant expression of Pax-2 in Danforth's short tail (Sd) mice.","date":"1993","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/8482415","citation_count":37,"is_preprint":false},{"pmid":"34545858","id":"PMC_34545858","title":"Reliable Identification of Endometrial Precancers Through Combined Pax2, β-Catenin, and Pten Immunohistochemistry.","date":"2022","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34545858","citation_count":35,"is_preprint":false},{"pmid":"9459485","id":"PMC_9459485","title":"Effects of PAX2 expression in a human fetal kidney (HEK293) cell line.","date":"1998","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9459485","citation_count":34,"is_preprint":false},{"pmid":"17082250","id":"PMC_17082250","title":"Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease.","date":"2006","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17082250","citation_count":34,"is_preprint":false},{"pmid":"21539742","id":"PMC_21539742","title":"Prospero and Pax2 combinatorially control neural cell fate decisions by modulating Ras- and Notch-dependent signaling.","date":"2011","source":"Neural development","url":"https://pubmed.ncbi.nlm.nih.gov/21539742","citation_count":32,"is_preprint":false},{"pmid":"19048125","id":"PMC_19048125","title":"WNT5A is regulated by PAX2 and may be involved in blastemal predominant Wilms tumorigenesis.","date":"2008","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/19048125","citation_count":32,"is_preprint":false},{"pmid":"24141260","id":"PMC_24141260","title":"Cotransfection of Pax2 and Math1 promote in situ cochlear hair cell regeneration after neomycin insult.","date":"2013","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24141260","citation_count":30,"is_preprint":false},{"pmid":"18485342","id":"PMC_18485342","title":"Ectopic Pax2 expression in chick ventral optic cup phenocopies loss of Pax2 expression.","date":"2008","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/18485342","citation_count":30,"is_preprint":false},{"pmid":"19505455","id":"PMC_19505455","title":"BMP7 and SHH regulate Pax2 in mouse retinal astrocytes by relieving TLX repression.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19505455","citation_count":30,"is_preprint":false},{"pmid":"21778682","id":"PMC_21778682","title":"WT1 and Pax2 re-expression is required for epithelial-mesenchymal transition in 5/6 nephrectomized rats and cultured kidney tubular epithelial cells.","date":"2011","source":"Cells, tissues, organs","url":"https://pubmed.ncbi.nlm.nih.gov/21778682","citation_count":28,"is_preprint":false},{"pmid":"7569406","id":"PMC_7569406","title":"Transcription factors in renal development: the WT1 and Pax-2 story.","date":"1995","source":"Seminars in nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/7569406","citation_count":27,"is_preprint":false},{"pmid":"25613757","id":"PMC_25613757","title":"Upregulation of PAX2 promotes the metastasis of esophageal cancer through interleukin-5.","date":"2015","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25613757","citation_count":27,"is_preprint":false},{"pmid":"23502471","id":"PMC_23502471","title":"PAX2 Expression in Ovarian Cancer.","date":"2013","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23502471","citation_count":26,"is_preprint":false},{"pmid":"30096791","id":"PMC_30096791","title":"UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer.","date":"2018","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/30096791","citation_count":26,"is_preprint":false},{"pmid":"21876729","id":"PMC_21876729","title":"PAX2 regulates ADAM10 expression and mediates anchorage-independent cell growth of melanoma cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21876729","citation_count":25,"is_preprint":false},{"pmid":"9712525","id":"PMC_9712525","title":"Expression of PAX2 gene during human development.","date":"1998","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/9712525","citation_count":25,"is_preprint":false},{"pmid":"32381599","id":"PMC_32381599","title":"Pax2 and Pax8 Proteins Regulate Urea Transporters and Aquaporins to Control Urine Concentration in the Adult Kidney.","date":"2020","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/32381599","citation_count":23,"is_preprint":false},{"pmid":"32203253","id":"PMC_32203253","title":"Clinical and genetic variability of PAX2-related disorder in the Japanese population.","date":"2020","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32203253","citation_count":23,"is_preprint":false},{"pmid":"25617721","id":"PMC_25617721","title":"Evidence for intermediate mesoderm and kidney progenitor cell specification by Pax2 and PTIP dependent mechanisms.","date":"2015","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/25617721","citation_count":23,"is_preprint":false},{"pmid":"22972769","id":"PMC_22972769","title":"Pax2 modulates proliferation during specification of the otic and epibranchial placodes.","date":"2012","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/22972769","citation_count":23,"is_preprint":false},{"pmid":"34908837","id":"PMC_34908837","title":"The Role of PAX2 in Neurodevelopment and Disease.","date":"2021","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/34908837","citation_count":21,"is_preprint":false},{"pmid":"9321680","id":"PMC_9321680","title":"Pax-2 in the chiasm.","date":"1997","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/9321680","citation_count":21,"is_preprint":false},{"pmid":"26373819","id":"PMC_26373819","title":"Divergent Roles of PAX2 in the Etiology and Progression of Ovarian Cancer.","date":"2015","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/26373819","citation_count":21,"is_preprint":false},{"pmid":"23137159","id":"PMC_23137159","title":"Signaling pathways of PAX2 and its role in renal interstitial fibrosis and glomerulosclerosis.","date":"2012","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/23137159","citation_count":20,"is_preprint":false},{"pmid":"31922217","id":"PMC_31922217","title":"PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming.","date":"2020","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31922217","citation_count":20,"is_preprint":false},{"pmid":"24992169","id":"PMC_24992169","title":"PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.","date":"2015","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/24992169","citation_count":20,"is_preprint":false},{"pmid":"35018885","id":"PMC_35018885","title":"Chromatin topology defines estradiol-primed progesterone receptor and PAX2 binding in endometrial cancer cells.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35018885","citation_count":19,"is_preprint":false},{"pmid":"25473752","id":"PMC_25473752","title":"Pax2 expression in simultaneously diagnosed WHO and EIN classification systems.","date":"2015","source":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/25473752","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48621,"output_tokens":7681,"usd":0.130539,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17116,"output_tokens":5692,"usd":0.11394,"stage2_stop_reason":"end_turn"},"total_usd":0.244479,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"PAX2 encodes a paired-domain protein expressed in nuclei of developing kidney and nervous system; the protein contains a conserved paired domain and an octapeptide sequence, and at least two protein isoforms are produced from differentially spliced mRNAs.\",\n      \"method\": \"cDNA cloning, sequencing, in situ hybridization, immunocytochemistry\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct cloning and immunolocalization in two independent papers, single lab, consistent results\",\n      \"pmids\": [\"1977574\", \"1977575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"PAX2 protein can bind a DNA sequence recognized by the Drosophila paired domain, confirming its function as a sequence-specific DNA-binding transcription factor; nuclear localization was demonstrated in condensing mesenchyme cells and their epithelial derivatives in the developing kidney.\",\n      \"method\": \"DNA-binding assay (EMSA using paired-domain recognition sequence), immunocytochemistry on developing kidney sections\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro DNA-binding assay plus direct immunolocalization, replicated across multiple tissue contexts\",\n      \"pmids\": [\"1311084\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"PAX2 protein function is required for the earliest phase of mesenchyme-to-epithelium conversion in the developing kidney; reduction of PAX2 protein with antisense oligonucleotides in mouse kidney organ cultures prevents mesenchyme aggregation and sequential morphological changes of epithelial cell formation.\",\n      \"method\": \"Antisense oligonucleotide-mediated loss-of-function in mouse kidney organ culture, immunostaining with uvomurulin and laminin antibodies\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct loss-of-function with defined cellular phenotype, replicated across multiple experiments; complemented by transgenic gain-of-function data in same era\",\n      \"pmids\": [\"8187639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Deregulated (persistent) expression of PAX2 in transgenic mice results in histologically abnormal and dysfunctional renal epithelium resembling congenital nephrotic syndrome, demonstrating that repression of PAX2 is required for normal terminal differentiation of renal epithelium.\",\n      \"method\": \"Transgenic mouse overexpression (four independently derived transgenic embryos and one line), histological and functional analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain-of-function confirmed in multiple independent transgenic lines with defined renal phenotype\",\n      \"pmids\": [\"8383297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"PAX2 is required for multiple steps of urogenital development: homozygous Pax2-null mice lack kidneys, ureters, and genital tracts due to dysgenesis of both ductal and mesenchymal components; Wolffian/Müllerian ducts degenerate, metanephric mesenchyme fails to undergo epithelial transformation, and expression of tissue-specific markers is de-regulated.\",\n      \"method\": \"Targeted gene knockout in mice (homozygous null), histological and molecular marker analysis\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — definitive loss-of-function knockout with multiple phenotypic readouts, widely replicated\",\n      \"pmids\": [\"8575306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The C-terminal serine/threonine/proline-rich region of PAX2 contains a potent transactivation domain (~55 amino acids) that is negatively regulated by adjacent extreme C-terminal sequences; both activating and inhibitory domains function as an independent regulatory module, conserved across PAX2, PAX5, PAX8, zebrafish Pax-b and sea urchin Pax-258.\",\n      \"method\": \"In vitro mutagenesis, transient transfection reporter assays, GAL4 DNA-binding domain fusion experiments in multiple cell types\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution via mutagenesis + reporter assays + GAL4 fusion, tested across multiple cell types and conserved in multiple species orthologs\",\n      \"pmids\": [\"8617244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"PAX2 is required for formation of the optic chiasm and closure of the optic fissure; PAX2-null mice show total ipsilateral optic tracts (agenesis of optic chiasma), coloboma due to optic fissure closure failure, and agenesis of the cochlea and spiral ganglion.\",\n      \"method\": \"Targeted Pax2 null mutation in mice, neuroanatomical tracing and histological analysis\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — definitive loss-of-function knockout with multiple independent phenotypic readouts across eye and ear\",\n      \"pmids\": [\"8951055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"PAX2 and PAX5 cooperate at the midbrain-hindbrain boundary organizer: compound heterozygous Pax5(+/-)Pax2(+/-) mice show severe loss of inferior colliculi and cerebellar vermis, and Pax5(-/-)Pax2(+/-) mice show complete deletion of posterior midbrain and cerebellum, demonstrating genetic cooperation between the two factors for normal organizer function.\",\n      \"method\": \"Double-mutant mouse genetics (Pax5 targeted knockout × Krd deletion of Pax2 locus), morphological analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via double-mutant mice with graded allele dosage, clearly defined phenotypic spectrum\",\n      \"pmids\": [\"9159136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PAX2 expression in human fetal kidney epithelial (HEK293) cells increases WT1 mRNA (~2-fold) and E-cadherin mRNA (~7-fold), and strongly suppresses vimentin mRNA (to ~8% of control), without affecting proliferation rate, suggesting PAX2 directly regulates mesenchyme-to-epithelium gene expression changes during nephrogenesis.\",\n      \"method\": \"Stable transfection with tetracycline-regulatable PAX2 expression vector, RT-PCR, Western blot\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay in cell culture with multiple gene readouts, single lab\",\n      \"pmids\": [\"9459485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Tlx, an orphan nuclear receptor, directly regulates Pax2 transcription; a Tlx binding site is present in the Pax2 promoter and is conserved between mouse and human, placing Tlx upstream of PAX2 in retinal development.\",\n      \"method\": \"Candidate target gene screen, promoter analysis, conservation of Tlx-binding site identified by sequence analysis; Tlx knockout mice showing loss of Pax2 in the retina\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding site identified and corroborated by Tlx knockout phenotype, single lab\",\n      \"pmids\": [\"10706625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Reduced Pax2 gene dosage (heterozygous) increases apoptosis in normal developing kidneys and inhibits cystic epithelium expansion in cpk polycystic kidney disease mice, without reducing proliferation, demonstrating that PAX2 normally suppresses apoptosis in renal epithelium.\",\n      \"method\": \"Genetic intercross (cpk × Pax2 heterozygous), histological quantification of cyst growth, apoptosis assays (TUNEL), proliferation assays\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — defined genetic dosage manipulation with multiple orthogonal readouts (cyst size, apoptosis, proliferation)\",\n      \"pmids\": [\"10694420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"PAX2 transactivation domain is specifically phosphorylated by c-Jun N-terminal kinase (JNK), but not ERK1/2 or p38 MAP kinases; JNK phosphorylation of PAX2 is coincident with enhanced PAX2-dependent transcription activation. PAX2 forms a complex with the JNK scaffolding protein JIP1, and this interaction is enhanced by the upstream kinase DLK.\",\n      \"method\": \"In vitro kinase assays with immunoprecipitated JNK and recombinant GST-Pax2 fusion proteins, transfection reporter assays, co-immunoprecipitation with JIP1\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with recombinant proteins, co-IP of complex, reporter assays all in one study\",\n      \"pmids\": [\"11700324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"PAX2 expression in mouse mammary gland is required for progesterone-stimulated secondary ductal branching and lobular development; PAX2 loss-of-function (transplant of PAX2-null parenchyma) prevents progesterone response. A PAX2–WT1 regulatory axis was identified, with PAX2 required for WT1 mRNA expression in the mammary gland.\",\n      \"method\": \"Mammary fat pad transplantation of PAX2-null tissue into wild-type hosts, RT-PCR for WT1, double-antibody immunohistochemistry for PAX2/WT1 co-localization\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined loss-of-function with specific progesterone-response phenotype and WT1 molecular readout, single lab\",\n      \"pmids\": [\"11850818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PAX2 and PAX8 together are essential for specification of the nephric lineage; mouse embryos lacking both Pax2 and Pax8 fail to form any nephric structures (pronephros or later kidneys), do not initiate Lim1 or c-Ret expression, and lose intermediate mesoderm by apoptosis. Retroviral misexpression of Pax2 alone is sufficient to induce ectopic nephric structures in chick intermediate mesoderm and genital ridge.\",\n      \"method\": \"Double-knockout mouse genetics, retroviral Pax2 misexpression in chick embryos, molecular marker analysis (Lim1, c-Ret), apoptosis assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — double-knockout plus gain-of-function rescue in a second species, multiple molecular readouts\",\n      \"pmids\": [\"12435636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Groucho/TLE family protein Grg4 interacts with PAX2 and suppresses PAX2 transactivation by specifically inhibiting JNK-mediated phosphorylation of the PAX2 activation domain; this inhibition depends on PAX2 binding to its target DNA and is independent of histone deacetylation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphorylation assays, reporter transactivation assays, DNA-binding dependency experiments\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro phosphorylation reconstitution plus co-IP of Grg4-PAX2 complex, with mechanistic dissection of DNA-binding and HDAC independence\",\n      \"pmids\": [\"14532124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Angiotensin II upregulates Pax2 protein and mRNA via the AT2 receptor (not AT1) in embryonic kidney mesenchymal-epithelial cells (MK4), and this signaling is mediated at least in part through the JAK2/STAT pathway; the stimulatory effect is blocked by the AT2 inhibitor PD123319, the JAK2 inhibitor AG490, and the tyrosine kinase inhibitor genistein, but not by AT1, p38, MEK, or JNK inhibitors.\",\n      \"method\": \"Pharmacological inhibitor dissection in embryonic kidney cell lines and kidney explant culture, Western blot, RT-PCR, immunofluorescence\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple inhibitor experiments with pathway dissection in two model systems, single lab\",\n      \"pmids\": [\"15153556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PAX2 directly activates WNT4 gene expression during kidney development: PAX2 protein binds three novel PAX2 recognition motifs in the 5'-flanking sequence of human WNT4 (confirmed by EMSA), activates WNT4 promoter activity ~5-fold in co-transfection assays, induces ~7-fold increase in endogenous WNT4 mRNA in proximal tubule cells, and Wnt4 mRNA is reduced ~60% in Pax2 heterozygous fetal kidney mesenchymal condensates.\",\n      \"method\": \"EMSA, co-transfection reporter assays, RT-PCR in cell line and Pax2 heterozygous fetal kidney\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct DNA binding (EMSA), promoter activation assay, and in vivo genetic dosage validation, multiple orthogonal methods\",\n      \"pmids\": [\"16368682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PAX2 regulates gene expression at the mid-hindbrain boundary including direct transcriptional activation of Brn1 (Pou3f3) via functional PAX2-binding sites in the Brn1 promoter and upstream regulatory element; PAX2-dependent targets also include En2, Sef, Tapp1, and Ncrms. Dominant-negative Brn1 in chick implicates Brn1 in Fgf8 regulation downstream of Pax2.\",\n      \"method\": \"cDNA microarray of FACS-sorted GFP+ cells from wild-type vs Pax2-null embryos; identification of PAX2-binding sites by transgenic lacZ reporter analysis; ectopic dominant-negative Brn1 electroporation in chick\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-scale expression profiling plus direct in vivo reporter validation of PAX2 binding sites plus functional rescue experiment in chick\",\n      \"pmids\": [\"15872005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Pax2 and Pax8 regulate Gata3 expression in the nephric duct: a cDNA microarray screen identified Gata3 as a gene specifically expressed in the pro/mesonephros and regulated by Pax proteins; Gata3 expression in the pronephric anlage coincides with Pax2/Pax8, suggesting direct upstream regulation.\",\n      \"method\": \"cDNA microarray screen of pro/mesonephros; Gata3 knockout phenotypic analysis (Ires-GFP knockin); molecular analysis of Ret expression in Gata3(-/-) nephric duct\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — microarray identification plus genetic loss-of-function with molecular readout, but direct Pax2 binding to Gata3 promoter not demonstrated in this paper\",\n      \"pmids\": [\"16319112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Pax2 activates the mid-hindbrain boundary enhancer of Brn1 and maintains its own expression via auto- and cross-regulatory control: functional PAX2/5/8-binding sites in a proximal enhancer maintain Pax2 expression at the mid-hindbrain boundary; an early 120 bp enhancer requires homeodomain binding sites (including a POU homeodomain site bound by Oct3/4) for initial activation.\",\n      \"method\": \"Transgenic reporter analysis in mice, site-directed mutagenesis of enhancer binding sites, BAC transgene deletion analysis, electrophoretic mobility assays\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis of cis-regulatory elements combined with in vivo transgenic reporter assays and BAC deletion validation\",\n      \"pmids\": [\"11807024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PAX2 mediates ER-dependent repression of ERBB2 transcription in response to tamoxifen in breast cancer cells: tamoxifen-ER complexes repress ERBB2 via a cis-regulatory element in the ERBB2 gene, and PAX2 is a critical mediator of this repression. PAX2 and the ER co-activator AIB1/SRC-3 compete for binding and regulation of ERBB2 transcription, with the outcome determining tamoxifen response.\",\n      \"method\": \"Reporter assays, ChIP, siRNA knockdown of PAX2, competition binding experiments between PAX2 and AIB1/SRC-3 at the ERBB2 locus in human breast cancer cell lines\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, reporter assays, and siRNA phenotypic rescue with defined molecular competitor, multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"19005469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PAX2 directly activates WNT5A gene expression; PAX2 binds to the WNT5A promoter (confirmed by chromatin immunoprecipitation and EMSA), and transactivation assays demonstrate direct PAX2-dependent regulation of WNT5A in HEK293 cells.\",\n      \"method\": \"Chromatin immunoprecipitation, EMSA, transactivation assays in HEK293 cells\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct DNA binding confirmed by both ChIP and EMSA plus functional transactivation assay\",\n      \"pmids\": [\"19048125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Pax2 coordinates optic cup morphogenesis and cell fate independently: in the absence of Pax2, otic progenitors fail to elongate due to loss of apically localized N-cadherin and N-CAM; misexpression of Pax2 leads to ectopic activation of both adhesion molecules but is not sufficient to confer otic identity, indicating Pax2 controls cell shape independently from cell identity.\",\n      \"method\": \"Pax2 loss-of-function and gain-of-function in chick inner ear, immunofluorescence for N-cadherin, N-CAM, otic marker expression\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complementary loss- and gain-of-function in same tissue with defined molecular adhesion molecule readout, single lab\",\n      \"pmids\": [\"20643116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BMP7 and SHH activate Pax2 expression in mouse retinal astrocyte precursors; SHH may regulate BMP7 expression, and BMP and SHH pathway members interact with TLX (a tailless transcription factor family repressor) to relieve TLX-mediated repression of Pax2 expression.\",\n      \"method\": \"In vitro and ex vivo retinal astrocyte precursor cultures with BMP7 and SHH treatment; pathway inhibitor experiments; demonstrated TLX interaction with BMP and SHH pathway members by co-immunoprecipitation\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional pathway dissection in primary cells with inhibitor experiments and co-IP of TLX interactions, single lab\",\n      \"pmids\": [\"19505455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PAX2 directly binds the ADAM10 promoter and regulates ADAM10 protein expression in renal cancer cells; PAX2 knockdown reduces ADAM10 (a major sheddase for L1-CAM and c-Met), leading to increased L1-CAM expression and activation of PI3K/Akt signaling via soluble L1-CAM.\",\n      \"method\": \"ChIP, PAX2 siRNA knockdown, PAX2 overexpression, L1-CAM and ADAM10 protein measurements in renal cancer cell lines\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms direct promoter binding, with downstream pathway validation by knockdown, single lab\",\n      \"pmids\": [\"21880579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PAX2 directly regulates ADAM10 expression in melanoma cells (confirmed by ChIP and PAX2 overexpression/siRNA); PAX2 knockdown inhibits anchorage-independent cell growth, migration, and invasion and restores cisplatin sensitivity in melanoma cells.\",\n      \"method\": \"ChIP, PAX2 siRNA knockdown, PAX2 overexpression, soft agar assays, migration/invasion assays, drug sensitivity assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms direct binding, multiple functional readouts by siRNA and overexpression, single lab\",\n      \"pmids\": [\"21876729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FSGS-associated PAX2 missense mutations perturb protein function by affecting DNA binding and transactivation activity, or by altering interaction with repressor proteins resulting in enhanced repressor activity; these effects were documented by in vitro functional studies guided by in silico structural modeling.\",\n      \"method\": \"In vitro functional studies (DNA-binding and transactivation assays), in silico structural modeling of PAX2 missense variants\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro functional assays with multiple mutants, structural modeling, but single lab\",\n      \"pmids\": [\"24676634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PAX2 specifies the intermediate mesoderm and renal progenitor cells through epigenetic mechanisms dependent on the adaptor protein PTIP: PAX2 recruits PTIP-dependent histone methyltransferase complexes to activate early Pax2 target genes; loss of PTIP in kidney organ culture prevents full activation of later-expressed Pax2 target genes, while early Pax2 targets remain on once activated. PAX2 also represses paraxial mesodermal fate.\",\n      \"method\": \"EGFP knock-in allele cell sorting, gene expression profiling of Pax2 mutant vs wild-type intermediate mesoderm cells, conditional PTIP deletion in kidney organ culture, chromatin analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (FACS-sorted transcriptomics, conditional PTIP KO, epigenetic mechanism) in a single rigorous study\",\n      \"pmids\": [\"25617721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PAX2 directly binds the IL-5 promoter and activates IL-5 expression in esophageal cancer cells, promoting tumor metastasis; two PAX2 binding sites were identified in the IL-5 promoter, and PAX2 stimulated IL-5 promoter activity, with ChIP confirming direct binding.\",\n      \"method\": \"ChIP, promoter reporter assays, PAX2 overexpression and shRNA knockdown in ESCC cell lines, microarray analysis\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assays confirm direct binding, functional invasion/metastasis assays, single lab\",\n      \"pmids\": [\"25613757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PAX2 and PAX8 are required in adult renal collecting duct epithelia for urine concentration: induced deletion of both Pax2 and Pax8 in adult mice causes severe polyuria attributable to loss of urea transporters (Slc14a2) and aquaporins in inner/outer medulla. Pax8 is induced by high-salt in collecting duct cells and activates Slc14a2 by recruiting a histone methyltransferase complex to its promoter.\",\n      \"method\": \"Inducible conditional knockout of Pax2 and/or Pax8 in adult mice, gene expression analysis, ChIP for histone methyltransferase complex recruitment to Slc14a2 promoter in inner medullary collecting duct cells\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible adult-specific conditional KO with defined physiological phenotype plus mechanistic ChIP for epigenetic target gene activation\",\n      \"pmids\": [\"32381599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PAX2 binds in the vicinity of estrogen-promoted progesterone receptor (PR) binding sites in endometrial cancer cells and fine-tunes ERalpha and PR interplay in transcriptional regulation; PAX2 knockdown alters expression of hormone-regulated genes at these 'progestin control regions' (PgCRs) which have open chromatin even before hormone exposure.\",\n      \"method\": \"ChIP-seq for PAX2, ER, PR in hormone-treated Ishikawa endometrial cancer cells; Hi-C; ATAC-seq; PAX2 siRNA knockdown with RNA-seq\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq, chromatin conformation (Hi-C), ATAC-seq, and functional knockdown in one rigorous study\",\n      \"pmids\": [\"35018885\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PAX2 is a sequence-specific DNA-binding transcription factor (via its paired domain) that activates or represses target genes (including WNT4, WNT5A, ERBB2, ADAM10, IL-5, Brn1/Pou3f3, Slc14a2) in a context-dependent manner; its transactivation activity is enhanced by JNK-mediated phosphorylation of its C-terminal serine/threonine-rich domain and suppressed by Groucho/TLE (Grg4)-mediated inhibition of that phosphorylation; it recruits PTIP-dependent histone methyltransferase complexes to epigenetically activate renal progenitor target genes; it is required for mesenchyme-to-epithelium transition and nephric lineage specification (cooperating with PAX8), and its expression must be extinguished for terminal differentiation of renal tubular epithelium, while persistent expression promotes cystic, dysplastic, or neoplastic renal growth.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PAX2 is a paired-domain, sequence-specific DNA-binding transcription factor that governs urogenital and neural development by activating or repressing lineage-specific target genes [#0, #1]. It is required for the earliest mesenchyme-to-epithelium conversion of the metanephric mesenchyme, and embryos lacking PAX2 (or both PAX2 and its partner PAX8) fail to form kidneys, ureters, and genital tracts, while PAX2/PAX8 double loss abolishes nephric lineage specification altogether and PAX2 misexpression alone induces ectopic nephric structures [#2, #4, #13]. PAX2 also patterns the optic chiasm, optic fissure, cochlea, and—cooperating with PAX5—the midbrain-hindbrain boundary organizer [#6, #7]. Its transcriptional outputs include direct activation of WNT4, WNT5A, the midbrain-hindbrain factor Brn1/Pou3f3, and a self-maintaining enhancer of its own locus, and it drives epithelial gene programs (raising WT1 and E-cadherin while suppressing vimentin) [#16, #21, #17, #19, #8]. PAX2 transactivation is positively regulated by JNK-mediated phosphorylation of its C-terminal serine/threonine-rich activation module—an interaction scaffolded by JIP1 and DLK—and is antagonized by Groucho/TLE protein Grg4, which suppresses this phosphorylation in a DNA-binding-dependent, HDAC-independent manner [#5, #11, #14]. PAX2 specifies intermediate mesoderm and renal progenitors epigenetically by recruiting PTIP-dependent histone methyltransferase complexes to activate target genes, and PAX2/PAX8 sustain adult collecting-duct urine-concentrating genes such as Slc14a2 through the same epigenetic machinery [#27, #29]. Because PAX2 suppresses renal epithelial apoptosis and its persistence blocks terminal differentiation, deregulated PAX2 produces dysplastic, cystic renal phenotypes, and PAX2 is co-opted in cancers where it regulates ERBB2, ADAM10, and IL-5 [#3, #10, #20, #24, #28]. FSGS-associated PAX2 missense mutations disrupt DNA binding and transactivation or enhance repressor interactions, linking PAX2 dysfunction to human renal disease [#26].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Establishing that PAX2 encodes a nuclear paired-domain protein expressed in developing kidney and nervous system defined it as a candidate developmental transcription factor and revealed isoform diversity.\",\n      \"evidence\": \"cDNA cloning, sequencing, in situ hybridization and immunocytochemistry\",\n      \"pmids\": [\"1977574\", \"1977575\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"DNA-binding activity not yet demonstrated\", \"functional roles of distinct isoforms unresolved\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Demonstrating that PAX2 binds a paired-domain recognition sequence confirmed it acts as a sequence-specific DNA-binding transcription factor in the developing kidney.\",\n      \"evidence\": \"EMSA with paired-domain recognition sequence plus immunolocalization on kidney sections\",\n      \"pmids\": [\"1311084\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"no endogenous target genes identified\", \"activator vs repressor function not yet defined\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Loss- and gain-of-function showed PAX2 is required for mesenchyme-to-epithelium conversion and that its persistence blocks terminal differentiation, defining a window of required expression.\",\n      \"evidence\": \"antisense knockdown in mouse kidney organ culture; transgenic overexpression in mice\",\n      \"pmids\": [\"8187639\", \"8383297\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"direct transcriptional targets driving conversion not identified\", \"mechanism of required down-regulation unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Targeted knockout established that PAX2 is essential across urogenital development, with null mice lacking kidneys, ureters, and genital tracts.\",\n      \"evidence\": \"homozygous Pax2-null mice with histological and marker analysis\",\n      \"pmids\": [\"8575306\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"cell-autonomous vs non-autonomous requirements not dissected\", \"molecular targets in each duct lineage unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Mapping the C-terminal transactivation module and extending null phenotypes to eye and ear revealed both the regulatory architecture of PAX2 and the breadth of its developmental roles.\",\n      \"evidence\": \"GAL4 fusion/mutagenesis reporter assays; Pax2-null neuroanatomical analysis\",\n      \"pmids\": [\"8617244\", \"8951055\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"signals controlling the inhibitory module unknown at this stage\", \"neural target genes not identified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Double-mutant genetics demonstrated PAX2-PAX5 cooperation at the midbrain-hindbrain organizer, establishing functional redundancy among PAX family members in dosage-sensitive patterning.\",\n      \"evidence\": \"Pax5 knockout × Pax2 (Krd) deletion compound-mutant mouse genetics\",\n      \"pmids\": [\"9159136\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"shared vs distinct target genes not resolved\", \"biochemical basis of cooperation unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Inducible PAX2 expression in human kidney epithelial cells linked PAX2 to the epithelial gene program by raising WT1 and E-cadherin and suppressing vimentin.\",\n      \"evidence\": \"tetracycline-regulated PAX2 stable transfection with RT-PCR and Western blot in HEK293\",\n      \"pmids\": [\"9459485\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"direct vs indirect regulation of these genes not established\", \"single cell-line context\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of Tlx as a direct upstream regulator and the demonstration that PAX2 suppresses renal epithelial apoptosis placed PAX2 within signaling hierarchies and clarified its growth-permissive role.\",\n      \"evidence\": \"promoter binding-site analysis with Tlx knockout; cpk × Pax2-heterozygous intercross with TUNEL and proliferation assays\",\n      \"pmids\": [\"10706625\", \"10694420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"anti-apoptotic target genes of PAX2 not identified\", \"Tlx site occupancy not validated in vivo by ChIP\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Discovery that JNK phosphorylates the PAX2 transactivation domain—scaffolded by JIP1/DLK—and that PAX2 controls progesterone-driven mammary branching connected signaling to PAX2 transcriptional output across tissues.\",\n      \"evidence\": \"in vitro JNK kinase assays, co-IP with JIP1, reporter assays; PAX2-null mammary fat-pad transplantation with WT1 readout\",\n      \"pmids\": [\"11700324\", \"11850818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"phosphoacceptor residues and their in vivo requirement not mapped\", \"MAPK pathway specificity in vivo not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defining PAX2/PAX8 redundancy for nephric lineage specification and the auto/cross-regulatory enhancer at the mid-hindbrain boundary revealed how PAX2 establishes and maintains its own expression domains.\",\n      \"evidence\": \"Pax2/Pax8 double-knockout and chick retroviral misexpression; transgenic reporter mutagenesis and BAC deletion of Pax2 enhancers\",\n      \"pmids\": [\"12435636\", \"11807024\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"direct targets initiating nephric specification not enumerated\", \"biochemical basis of PAX2/PAX8 functional equivalence unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showing that Grg4/TLE suppresses PAX2 transactivation by inhibiting JNK-mediated phosphorylation defined the molecular switch toggling PAX2 between active and repressed states.\",\n      \"evidence\": \"co-IP, in vitro phosphorylation, reporter assays with DNA-binding-dependency tests\",\n      \"pmids\": [\"14532124\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"in vivo developmental contexts of Grg4 antagonism not mapped\", \"how Grg4 mechanistically blocks the kinase unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Linking Angiotensin II/AT2 signaling through JAK2/STAT to PAX2 induction extended the upstream regulatory network controlling PAX2 abundance in nephrogenic cells.\",\n      \"evidence\": \"pharmacological inhibitor dissection in embryonic kidney cells and explants\",\n      \"pmids\": [\"15153556\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"direct STAT binding to the Pax2 promoter not shown\", \"single-lab pharmacological evidence\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Direct identification of WNT4, Brn1/Pou3f3, and other targets (with En2, Sef, Gata3) converted PAX2 from a genetically required factor into a defined transcriptional activator of developmental programs.\",\n      \"evidence\": \"EMSA/ChIP and reporter assays for WNT4; microarray plus transgenic lacZ reporter validation for Brn1 and mid-hindbrain targets; microarray for Gata3\",\n      \"pmids\": [\"16368682\", \"15872005\", \"16319112\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"genome-wide direct binding map not yet available\", \"Gata3 direct promoter binding not demonstrated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of WNT5A as a direct target and the discovery that PAX2 mediates tamoxifen-induced ERBB2 repression revealed PAX2 functions in cancer-relevant transcriptional contexts.\",\n      \"evidence\": \"ChIP/EMSA/reporter assays for WNT5A; ChIP, siRNA, and AIB1/SRC-3 competition assays at ERBB2 in breast cancer cells\",\n      \"pmids\": [\"19048125\", \"19005469\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"determinants of PAX2 activator-vs-repressor outcome at a given locus unresolved\", \"in vivo relevance of ERBB2 repression beyond cell lines\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating PAX2 direct regulation of ADAM10 in renal cancer and melanoma connected PAX2 to sheddase-driven L1-CAM/PI3K-Akt signaling and tumor cell aggressiveness.\",\n      \"evidence\": \"ChIP, siRNA, overexpression with invasion/migration and drug-sensitivity assays in renal and melanoma cell lines\",\n      \"pmids\": [\"21880579\", \"21876729\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"in vivo tumor relevance not established\", \"single-lab cell-line evidence\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Establishing the PAX2-PTIP axis showed that PAX2 specifies renal progenitors epigenetically by recruiting histone methyltransferase complexes, and identification of the IL-5 target extended its oncogenic reach.\",\n      \"evidence\": \"FACS-sorted transcriptomics with conditional PTIP deletion in kidney organ culture; ChIP and reporter assays for IL-5 in ESCC cells\",\n      \"pmids\": [\"25617721\", \"25613757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"identity of the recruited HMT complex components not fully defined\", \"how early vs late targets are differentially maintained mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Inducible adult deletion revealed an ongoing PAX2/PAX8 requirement for urine concentration via epigenetic activation of Slc14a2 and aquaporins, showing PAX2 function extends beyond development.\",\n      \"evidence\": \"inducible conditional Pax2/Pax8 knockout in adult mice with expression analysis and ChIP for HMT recruitment to Slc14a2\",\n      \"pmids\": [\"32381599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"relative contributions of PAX2 vs PAX8 in adult collecting duct not fully separated\", \"salt-sensing mechanism upstream of induction unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Genome-wide mapping in endometrial cancer placed PAX2 at estrogen/progesterone-responsive regulatory regions, defining a role in fine-tuning hormone-receptor transcriptional interplay.\",\n      \"evidence\": \"PAX2/ER/PR ChIP-seq, Hi-C, ATAC-seq and siRNA RNA-seq in Ishikawa cells\",\n      \"pmids\": [\"35018885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"mechanism by which PAX2 modulates ER/PR output at PgCRs unresolved\", \"in vivo endometrial relevance not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Functional characterization of FSGS-associated PAX2 missense variants established that disease mutations act by impairing DNA binding/transactivation or enhancing repressor interactions, linking PAX2 dysfunction to human renal disease.\",\n      \"evidence\": \"in vitro DNA-binding and transactivation assays guided by in silico structural modeling\",\n      \"pmids\": [\"24676634\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"genotype-phenotype correlations not established in vivo\", \"single-lab functional assays\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PAX2 selects between activation and repression at a given locus, and the full composition of the histone methyltransferase machinery it recruits, remain unresolved.\",\n      \"evidence\": \"no single timeline study reconciles context-dependent activator/repressor switching with the recruited epigenetic complexes\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"determinants of activator-vs-repressor outcome unknown\", \"subunit composition of recruited HMT complexes incompletely defined\", \"structural basis of paired-domain target selection in vivo not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 16, 21, 24]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [5, 16, 17, 20, 21]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [14, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 4, 6, 7, 13]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [16, 17, 20, 21]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [27, 29]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 26]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PAX8\", \"PAX5\", \"TLE4\", \"JIP1\", \"PTIP\", \"WT1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}